Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is focused on the research, development and commercialisation of clinically validated cannabinoid based medicines.
The company owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development.